1: (ROOT (S (NP (NNP Mount) (NNP Sina) (HYPH -) (NNP Sorrento) (CD COVI-19) (NNS VentureCollaborations)) (VP (VBP are) (VP (VBG being) (VP (VBN formed) (PP (IN across) (NP (DT the) (NN board))) (S (VP (TO to) (VP (VB develop) (NP (NP (NN testing) (, ,) (NNS vaccines) (CC and) (NNS drugs)) (SBAR (S (VP (TO to) (VP (VB utilize) (PP (IN against) (NP (NP (NNP SAR) (HYPH -) (CD Co-2)) (SBAR (WHNP (WDT which)) (S (VP (VBZ has) (VP (VBN raised) (NP (NP (NNS concerns)) (PP (IN about) (NP (NP (NP (DT the) (NN potential)) (PP (IN of) (NP (NP (DT the) (NN product)) (VP (VBG being) (VP (VBN developed)))))) (, ,) (NP (ADVP (RB especially)) (NP (NP (DT the) (NNS ones)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN had) (VP (VBN rushed) (NP (NNS expeditions))))))))))))))))))))))))))))) (. .)))
2: (ROOT (S (NP (JJ Many)) (VP (VBP are) (VP (VBG beginning) (S (VP (TO to) (VP (VB worry) (SBAR (IN that) (S (NP (DT the) (HYPH COVI-19) (NN virus)) (VP (MD will) (, ,) (PP (IN like) (NP (JJ many) (NNS others))) (, ,) (VP (VB mutate) (CC or) (VB develop) (NP (NP (DT a) (NN way)) (SBAR (S (VP (TO to) (VP (VB get) (PP (IN around) (NP (NP (NP (DT the) (NNS antibodies)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (PP (IN under) (NP (NN development))))))) (SBAR (WHNP (WDT that)) (S (VP (VBP target) (NP (NP (NP (DT the) (NN virus) (POS 's)) (NN spike) (NN protein)) (SBAR (WHNP (WDT which)) (S (VP (VBZ facilitates) (NP (NP (DT the) (NN infection)) (PP (IN of) (NP (JJ healthy) (NNS cells))))))))))))))))))))))))))) (. .)))
3: (ROOT (S (S (VP (TO To) (VP (VB address) (NP (DT this) (NN concern))))) (NP (NNP Sorrento) (NNP Therapeutics)) (VP (VBZ is) (VP (VBG working) (PP (IN on) (S (VP (VBG developing) (NP (NP (DT an) (NN antibody) (NN cocktail)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VP (VB bind) (PP (IN to) (NP (CD three) (JJ different) (NNS epitopes)))) (CONJP (RB rather) (IN than)) (VP (VBG targeting) (NP (NP (QP (RB just) (CD one)) (NN point)) (PP (IN on) (NP (DT the) (NN spike) (NN protein))))) (SBAR (IN as) (S (NP (NP (JJS most)) (PP (IN of) (NP (NP (DT the) (JJ current) (NN work)) (ADVP (RB elsewhere))))) (VP (VBZ is) (VP (VBG doing))))))))))))))) (. .)))
4: (ROOT (S (NP (DT The) (NN company)) (VP (VBZ has) (ADVP (RB also)) (VP (VBN teamed) (PRT (RP up)) (PP (IN with) (NP (NP (NML (NNP Mount) (NNP Sinai)) (NNP Health) (NNP System)) (PP (IN in) (NP (NNP New) (NNP York))))) (S (VP (TO to) (VP (VB help) (ADVP (RBR further)) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (DT the) (NN cocktail) (NN treatment))))))))) (. .)))
5: (ROOT (S (`` `) (S (SBAR (IN If) (S (S (NP (CD one) (NN epitope)) (VP (VBZ mutates))) (CC and) (S (NP (NP (CD one)) (PP (IN of) (NP (DT the) (NNS antibodies)))) (VP (VBZ does) (RB not) (VP (VB do) (NP (PRP$ its) (NN job)) (ADVP (RB anymore))))))) (, ,) (NP (DT the) (JJ other) (CD two)) (VP (MD can) (VP (VB do) (NP (DT the) (NN job))))) (, ,) ('' ') (NP (NP (NNP Henry) (NNP Ji)) (, ,) (NP (NNP P) (. ..)) (, ,) (NP (NP (NN CEO)) (PP (IN of) (NP (NNP Sorrento)))) (, ,)) (VP (VBD told) (NP (NNP FierceBiotechResearch))) (. .)))
6: (ROOT (S (NP (PRP They)) (VP (VBP are) (ADJP (JJ synergistic))) (. .) ('' ')))
7: (ROOT (S (PP (VBG According) (PP (IN to) (NP (NNP Ji)))) (, ,) (S (NP (DT the) (NN cocktail) (NN therapy)) (VP (VBZ is) (VP (VBG being) (VP (VBN called) (S (NP (NNP COV) (HYPH -) (NNP SHIELD))))))) (, ,) (CC and) (S (NP (PRP it)) (VP (VBD started) (PP (IN with) (NP (NP (NP (DT a) (NN diagnostic)) (VP (VBN developed) (PP (IN at) (NP (NNP Sinai))))) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB screen) (NP (NP (CD 1,000) (NNS people)) (VP (VBN believed) (S (VP (TO to) (VP (VB have) (VP (VBN recovered) (PP (IN from) (NP (DT the) (NN disease)))))))))))))))))))) (. .)))
8: (ROOT (S (NP (NP (NNS Samples)) (PP (IN from) (NP (DT these) (NNS patients)))) (VP (VBP are) (VP (VBG being) (VP (VBN used) (S (VP (TO to) (VP (VB identify) (NP (NP (QP (DT a) (JJ few) (NN dozen)) (NNS antibodies)) (SBAR (WHNP (WDT that)) (S (VP (VBP stand) (NP (NP (DT the) (JJS best) (NNS odds)) (PP (IN of) (S (VP (VBG being) (ADJP (JJ able) (S (VP (TO to) (VP (VB neutralize) (NP (NNP SAR) (HYPH -) (CD Co-2)))))))))))))))))))) (. .)))
9: (ROOT (S (NP (NNP Sorrento)) (VP (MD will) (ADVP (RB also)) (VP (VB be) (VP (VBG working) (PP (IN with) (NP (NP (NP (NNS scientists)) (PP (IN at) (NP (DT the) (NML (NML (NNP University)) (PP (IN of) (NP (NNP Texas)))) (NNP Medical) (NNP Branch)))) (SBAR (WHNP (WP who)) (S (VP (MD will) (ADVP (RB then)) (VP (VB be) (VP (VBG testing) (NP (NP (DT the) (NNS antibodies)) (PP (IN against) (NP (DT the) (JJ live) (NN virus)))) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (VP (TO to) (VP (VB achieve) (NP (NP (JJ total) (NN inhibition)) (PP (IN of) (NP (JJ viral) (NN infection))))))))))))))))))))) (. .)))
10: (ROOT (S (SBAR (IN Once) (S (NP (DT the) (JJ top) (NNS performers)) (VP (VBP are) (VP (VBN identified))))) (NP (DT the) (NN company)) (VP (MD will) (VP (VB present) (NP (DT the) (NNS selections)) (PP (IN to) (NP (NNP Sinai))) (S (VP (TO to) (ADVP (RB further)) (VP (VB analyze) (NP (DT the) (NNS selections))))))) (. .)))
11: (ROOT (S (SBAR (IN Once) (S (NP (DT the) (NN company)) (VP (VBZ moves) (PP (IN into) (NP (NP (NML (NN phase) (CD 1)) (NNS trials)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN hoped) (S (VP (TO to) (VP (VB begin) (PP (IN in) (NP (DT the) (JJ third) (NN quarter))))))))))))))) (, ,) (NP (NNP Sinai)) (VP (MD may) (ADVP (RB also)) (VP (VB serve) (PP (IN as) (NP (NP (DT the) (JJ clinical) (NN testing) (NN site)) (PP (IN for) (NP (NNP COV) (HYPH -) (NNP SHIELD))))))) (. .)))
12: (ROOT (S (NP (NNP Sorrento)) (VP (VBZ has) (VP (VBN entered) (NP (DT the) (NN field)) (S (VP (TO to) (VP (VB join) (NP (NP (NP (DT the) (NNS companies)) (VP (VBG working) (S (VP (TO to) (VP (VB develop) (NP (NP (NNS antibodies)) (SBAR (S (VP (TO to) (VP (VB neutralize) (NP (CD COVI-19)))))))))))) (PP (IN along) (PP (IN with) (NP (NP (NNS others)) (PP (JJ such) (IN as) (NP (NP (NNP Eli) (NNP Lilly)) (SBAR (WHNP (WP who)) (S (ADVP (RB recently)) (NP (QP ($ paid$) (CD 10) (CD million))) (PP (IN to) (NP (NNP Junshi) (NNP Biosciences))) (PP (IN for) (NP (DT the) (NN right) (S (VP (TO to) (VP (VB c) (HYPH -) (VB develop) (CC and) (VB market) (NP (NP (DT a) (JJ human) (JJ monoclonal) (NN antibody)) (PP (IN against) (NP (DT the) (NN disease)))))))))))))))))))))) (. .)))
13: (ROOT (S (ADVP (RB However)) (, ,) (NP (NNP Regeneron)) (VP (VP (VBZ has) (VP (VBN identified) (NP (CD two) (VBG neutralizing) (NNS antibodies)))) (CC and) (VP (VBZ is) (VP (VBN considered) (S (VP (S (VP (TO to) (VP (VB be) (NP (NP (DT the) (JJ front) (NN runner)) (PP (IN in) (NP (DT the) (NN race))))))) (PP (IN with) (NP (NNS plans) (S (VP (TO to) (VP (VB move) (NP (PRP$ their) (NN cocktail)) (PP (IN to) (NP (NN testing))) (ADVP (ADVP (RB as) (RB early)) (PP (IN as) (NP (NNP June) (CD 2020)))))))))))))) (. .)))
14: (ROOT (S (S (VP (VBG Neutralizing) (NP (NNS antibodies)))) (VP (VBZ does) (RB not) (VP (VB come) (PP (IN without) (NP (NP (NNS risks)) (PP (IN of) (NP (NP (DT the) (NN possibility)) (PP (IN of) (NP (NP (NN backfiring)) (PP (IN in) (NP (NP (DT the) (ADJP (NN antibody) (JJ dependent)) (NN enhancement) (NN process)) (, ,) (SBAR (WHADVP (WRB whereby)) (S (NP (DT the) (NN virus)) (VP (MD can) (VP (VB use) (NP (DT the) (NNS antibodies)) (S (VP (TO to) (VP (VB bolster) (NP (DT the) (NN infection))))))))))))))))))) (. .)))
15: (ROOT (S (NP (NNP Regeneron)) (VP (VBZ suggests) (S (VP (TO to) (VP (VB have) (VP (VBN addressed) (NP (DT this) (NN concern)))))) (S (VP (VBG expressing) (NP (NN confidence) (SBAR (IN that) (S (NP (PRP$ their) (JJ experimental) (NN cocktail)) (VP (MD can) (VP (VB avoid) (NP (NNP ADE)) (PP (IN by) (S (VP (VBG targeting) (NP (`` `) (NP (ADJP (RB uber) (JJ stealth)) (JJ constant) (NNS regions)) ('' ') (PP (IN of) (NP (DT the) (NN virus))))))))))))))) (. .)))
16: (ROOT (S (S (NP (NNS Antibodies)) (VP (VBP are) (VP (VBG being) (VP (VBN engineered) (PP (IN by) (NP (NNP Sorrento))) (S (VP (TO to) (RB not) (VP (VB bind) (PP (IN to) (NP (NP (DT the) (NN receptor)) (PP (IN on) (NP (NP (JJ immune) (NNS cells)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (VP (VBN believed) (S (VP (TO to) (VP (VB cause) (NP (NNP ADE)))))))))))))))))))) (: ;) (S (NP (NNS antibodies)) (VP (MD will) (ADVP (RB also)) (VP (VB be) (VP (VBN selected) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (NP (NP (JJ different) (NNS mechanisms)) (PP (IN for) (S (VP (VBG neutralizing) (NP (DT the) (NN virus)) (S (VP (TO to) (VP (VB reduce) (NP (NP (DT the) (NN chance)) (PP (IN of) (S (NP (NNS patients)) (VP (VBG becoming) (ADJP (JJ resistant) (PP (IN to) (NP (NN treatment)))))))))))))))))) (, ,) (PP (VBG according) (PP (IN to) (NP (NP (NNP Robert) (NNP Allen)) (SBAR (WHNP (WP who)) (S (VP (VBZ is) (NP (NP (DT the) (NN vice) (NN president)) (PP (IN of) (NP (NML (ADJP (JJ antiviral) (CC and) (JJ oncolytic)) (NN immunotherapy)) (NN development))) (PP (IN for) (NP (NNP Sorrento)))))))))))))) (. .)))
17: (ROOT (S ('' `) (S (NP (NP (DT Some)) (PP (IN of) (NP (PRP them)))) (VP (VBP are) (VP (VBG going) (S (VP (TO to) (VP (VB neutralize) (PP (IN through) (NP (NP (JJ direct) (NN blocking)) (PP (IN between) (NP (NP (NN spike)) (CC and) (NP (NP (NN ACE2)) (, ,) ('' ') (NP (NP (DT the) (NN receptor)) (SBAR (WHNP (WDT that)) (S (VP (VBZ helps) (S (NP (DT the) (NN virus)) (VP (VB infect) (NP (JJ human) (NNS cells))))))))))))))))))) (, ,) (NP (NNP Allen)) (VP (VBD said)) (. .)))
18: (ROOT (S (NP (NNS Others)) (VP (VBP are) (VP (VBG going) (S (VP (TO to) (VP (VB neutralize) (PP (IN through) (NP (DT a) (ADJP (DT no) (HYPH -) (VBG blocking)) (NN mechanism)))))))) (. .)))
19: (ROOT (S (NP (PRP We)) (VP (VBP 're) (ADJP (JJ able) (S (VP (TO to) (VP (VB create) (NP (NP (DT a) (JJR higher) (NN barrier)) (PP (IN to) (NP (NN resistance)))) (NP (DT that) (NN way))))))) (. .) ('' ')))
20: (ROOT (S (NP (DT The) (NN company)) (VP (VBZ is) (VP (VBG setting) (PRT (RP out)) (PP (IN on) (NP (DT this) (NN venture))) (PP (IN after) (S (VP (VBG avoiding) (NP (NP (DT a) (NN takeover) (NN bid)) (PP (IN from) (NP (DT an) (NN equity) (NN firm))) (PP (IN in) (NP (NNP January) (CD 2020))))))) (, ,) (S (VP (VBG disclosing) (SBAR (S (NP (PRP it)) (VP (VBD received) (NP (NP (NP (NP (DT a) (NN buyout) (NN bid)) (NP ($ of$) (CD 7))) (NP (DT a) (NN share))) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (NP (PDT twice) (DT the) (NN trading) (NN price)) (PP (IN at) (NP (DT the) (NN time)))))))))))))) (. .)))
21: (ROOT (S (PP (IN Despite) (NP (NP (NP (DT the) (VBG increasing) (NN amount)) (PP (IN of) (NP (NN competition)))) (VP (VBG rushing) (S (VP (TO to) (VP (VB develop) (CC and) (VB market) (PP (IN against) (NP (CD COVI-19))))))))) (, ,) (NP (NP (NNP Sorrento)) (CC and) (NP (PRP$ its) (JJ academic) (NNS collaborators))) (VP (VBP are) (ADJP (JJ confident) (SBAR (S (NP (PRP they)) (VP (MD will) (VP (VB be) (ADJP (JJ able) (S (VP (TO to) (VP (VB work) (ADVP (RB quickly)) (S (VP (TO to) (VP (VB discover) (NP (NP (DT an) (JJ effective) (NN cocktail)) (SBAR (S (VP (TO to) (VP (VB utilize) (PP (IN against) (NP (DT the) (NN disease))))))))))))))))))))) (. .)))
22: (ROOT (S (NP (DT The) (NN company)) (VP (VP (VBZ is) (ADJP (JJ aware) (PP (IN of) (NP (PDT all) (DT the) (NNS rivals))))) (CC and) (VP (VBZ says) (SBAR (S (NP (EX there)) (VP (VBZ is) (ADVP (RB still)) (NP (NP (JJ much) (NN work)) (SBAR (S (VP (TO to) (VP (VB do)))))) (SBAR (IN before) (S (NP (DT any) (NN treatment)) (VP (MD will) (VP (VB be) (ADJP (JJ ready) (PP (IN for) (NP (JJ clinical) (NN testing))))))))))))) (. .)))
23: (ROOT (S (`` `) (S (NP (DT The) (NML (NNP Mount) (NNP Sinai)) (NN collaboration)) (VP (VBZ is) (ADJP (RB very) (JJ important) (PP (IN for) (NP (PRP us)))) (, ,) (SBAR (IN because) (S (NP (PRP they)) (VP (VP (VBD screened) (NP (CD 1,000) (NNS samples))) (CC and) (VP (VBD picked) (NP (DT the) (ADJP (NNS highes) (HYPH -) (VBN protected)) (NNS people)))))))) (, ,) ('' ') (NP (NNP Ji)) (VP (VBD said)) (. .)))
24: (ROOT (S (NP (PRP We)) (VP (VBP expect) (S (VP (TO to) (VP (VB be) (ADJP (JJ able) (S (VP (TO to) (VP (VB isolate) (NP (ADJP (RB very) (JJ potent)) (NNS antibodies)))))))))) (. .)))
25: (ROOT (S (NP (PRP We)) (VP (VBP do) (`` ') (RB t) (VP (VB know) (SBAR (WHNP (WHNP (WDT which)) (PP (IN of) (NP (DT these) (NNS antibodies)))) (S (VP (MD will) (VP (VB be) (ADJP (JJ useful)))))))) (. .)))
26: (ROOT (S (S (ADVP (RB Maybe)) (NP (NP (DT some)) (PP (IN of) (NP (PRP them)))) (, ,) (ADVP (RB maybe)) (NP (NN none))) (, ,) ('' ') (NP (PRP he)) (VP (VBD said)) (. .)))
27: (ROOT (S (SBAR (WHNP (WP Whoever)) (S (VP (VBZ has) (NP (DT the) (JJS best) (NN antibody))))) (VP (VBZ wins)) (. .) ('' ')))
